[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-b-cell-lymphoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100545153","phase-1-treatment-of-relapsed-or-refractory-b-cell-lymphoma-with-chimeric-antigen-receptor-car-t-cell-therapy-produced-by-a-new-technology-100545153",false,"NCT06378190","Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology","Multicentre Phase I\u002FIIa Study of Infusion of Autologous Peripheral Blood T Lymphocytes Expanded and Genetically Modified Using Sleeping Beauty Family Transposons to Express a Chimeric Antigenic Receptor With Anti-CD19 Specificity Conjugated to the 4-1BB Co-stimulatory Region and CD3z and huEGFRt Signal Transmission (TranspoCART19) in Patients With Relapsed or Refractory B-cell Lymphoma","TranspoCART19","Inclusion Criteria:\n\n1. Patients diagnosed with relapsed or refractory B-cell lymphoma (Diffuse large B-cell lymphoma, Primary diffuse large B-cell lymphoma of the Central Nervous System (CNS), Mantle cell lymphoma, Follicular lymphoma grades 1, 2 or 3a or Marginal lymphoma, including splenic, nodal and MALT).\n2. Age over 18 years and under 80 years.\n3. Functional status Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. Patients with ECOG 2 may be included if motivated by haematological disease (Annex 3).\n4. Adequate bone marrow haematopoietic reserve.\n5. Life expectancy of at least 2 months.\n6. Adequate venous access for lymphapheresis. Absence of contraindications for lymphapheresis.\n7. Signed informed consent (patient or legal guardian).\n\nExclusion Criteria:\n\n1. Patients who, in the opinion of a physician, may benefit from other approved potentially curative therapeutic options, including commercial CAR-Ts.\n2. Treatment with any experimental or non-commercialised substance in the four weeks prior to recruitment, or who are actively participating in another therapeutic clinical trial.\n3. Diagnosis of another neoplasm, past or present. Patients who have been in complete remission for more than 3 years, or with a history of non-melanoma skin cancer or completely resected carcinoma in situ may be included. A current or previous history of clonal T-lymphocytes is also an exclusion criterion.\n4. Early relapse after allogeneic haematopoietic stem cell transplantation (less than 3 months for lymphapheresis, less than 6 months for TranspoCART19 infusion) or patients on active immunosuppressive treatment for graft-versus-recipient disease (corticosteroids or other systemic immunosuppressants).\n5. Active infection requiring systemic medical treatment.\n6. HIV infection.\n7. Concurrent and uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric illnesses that in the opinion of the investigator pose a risk to the patient.\n8. Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBcore antibodies, a hepatitis B virus DNA test will be required, and if the result is positive the patient will be excluded.\n9. Positive serology for hepatitis C virus (HCV), defined as a positive test for anti-HCV antibodies that is confirmed by Recombinant immunoblot assay (RIBA).\n10. Severe organ involvement, defined as cardiac ejection fraction \\\u003C40%; diffusing capacity of the lungs for carbon monoxide (DLCO) \\\u003C40%; calculated glomerular filtration rate \\\u003C30 ml\u002Fmin; baseline O2 saturation \\\u003C92%; bilirubin \\> 2 times upper limit of normal (unless due to Gilbert's syndrome) or transaminases \\> 2.5 upper limit of normal.\n11. Pregnant or lactating women. Women of childbearing age should have a negative pregnancy test at screening.\n12. Women of childbearing age, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective methods of contraception\\* from the start of the study until the end of the study.\n13. Men who are unable or unwilling to use highly effective methods of contraception\\* from the start of the study until the end of the study.\n14. Need to take glucocorticoids chronically in doses greater than 10 mg\u002Fday of prednisone (or equivalent) or other chronic immunosuppressants.\n15. Previous anti-CD19 CAR-T therapy. Previous treatment with other anti-CD19 strategies is permitted, provided that CD19 expression has been confirmed in the tumour biopsy.\n16. Hypersensitivity to the active substance or to any of the excipients.","ALL","18 Years","80 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed\u002Frefractory B-lymphoma. The main questions it aims to answer are:\n\nMaximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.",[29,30],"Refractory B-Cell Lymphoma","B-cell Lymphoma Recurrent","RECRUITING","2026-04-13",{"date":34,"type":35},"2026-04-16","ACTUAL",{"date":37,"type":35},"2024-03-11",{"date":39,"type":22},"2030-07",{"name":41,"class":42},"Instituto de Investigación Biomédica de Salamanca","OTHER",8,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100385614","study-of-car-t-therapy-in-older-patients-100385614","NCT04300998","Study of CAR-T Therapy in Older Patients","Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation","Inclusion Criteria:\n\n* are ≥60 years old (all cohorts)\n* have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)\n* able to speak and understand English (cohort 1 and 4 only)\n* have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)\n\nExclusion Criteria:\n\n* Any prior commercial or investigational CAR T therapy (all cohorts)\n* Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)\n* History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\\>60 minutes), as per medical records or patient report (cohort 1 only)\n* Current ongoing substance abuse and\u002For history of substance abuse, as per medical records or patient report (cohort 1 only)\n* History of CNS disease (cohort 4 only)","60 Years",{"count":53,"type":22},154,"OBSERVATIONAL","This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.",[57,29,58,59,60,61],"Lymphoma","Lymphoma, B-Cell","DLBCL NOS","High-grade B-cell Lymphoma","Multiple Myeloma",[57,63,64,60,59,29,65,66],"CART therapy","relapsed refractory large B-cell lymphoma","19-452","Memorial Sloan Kettering Cancer Center","2026-04-01",{"date":69,"type":35},"2026-04-07",{"date":71,"type":35},"2020-03-04",{"date":73,"type":22},"2027-03-04",{"name":66,"class":42},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":75},"100528255","phase-2-chidamide-combined-with-linperlisibon-for-the-treatment-of-refractoryrelapsed-follicular-lymphoma-100528255","NCT06158386","Chidamide Combined With Linperlisibon for the Treatment of Refractory\u002FRelapsed Follicular Lymphoma","A Multicenter, Prospective, Single-arm Clinical Study on the Treatment of Refractory\u002FRelapsed Follicular Lymphoma (R\u002FRFL) With Chidamide Combined With Linperlisib","Inclusion Criteria:\n\n1. The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed.\n2. Age ≥18 years old, regardless of gender.\n3. The estimated survival time is more than 3 months.\n4. ECOG ≤ 2.\n5. Be able to follow the requirements of the research plan.\n6. The patients have at least one measurable lesion (any length of lymph node lesion \\> 1.5cm or any length of extranodal lesion \\> 1 cm) examined by computed tomography (CT)\u002F magnetic resonance imaging (MRI).\n7. Be able to understand and voluntarily provide informed consent.\n\nExclusion Criteria:\n\n1. CNS involvement (current or previous).\n2. Clinical evidence of transformation to a more aggressive subtype of lymphoma\n3. Impaired bone marrow function: neutrophils \\\u003C 1.5× 10\\*9\u002FL, HB \\\u003C 80 g\u002FL, PLT \\\u003C 75×10\\*9 \u002FL, Impaired liver function, defined as serum total bilirubin \\> 1.5 x ULN or serum ALT and AST \\> 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT \\> 5x ULN, Renal glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin.\n4. PT INR\\>1.5ULN or APTT\\> 1.5 ULN, Serum amylase or lipase \\> 1ULN.\n5. Patients with active infection of the human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), if patients with HBV infection with HBsAg or hepatitis B core antibody (HBcAb) positive\\] but HBV DNA negative can be included, However, these patients need continuous antiviral treatment and HBV DNA PCR detection every cycle after enrollment.\n6. Patients with CMV infection (IgM positive or CMV DNA was positive by PCR.)\n7. Meet any of the following criteria related to visceral function: all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF\\>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )\\\u003C40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mgHg).\n8. Have a history of stroke or intracranial hemorrhage within 6 months before drug administration for the first time.\n9. Major surgery was performed within 4 weeks before enrollment.\n10. Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use).\n11. Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment.\n12. The last time you participated in clinical trials of other drugs before enrollment was less than 2 weeks or the last time you used small molecular drugs (such as antibody drugs) was less than 4 weeks.\n13. The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment.\n14. Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration.\n15. Take a strong inducer or inhibitor of cytochrome P4503A4 (CYP3A4) within 2 weeks before the first drug administration (3 weeks for Hypericum perforatum)\n16. Before the first drug administration, the toxic reaction of previous anti-tumor therapy has not recovered to ≤1 level (except alopecia).\n17. Patients with uncontrolled systemic infection requiring intravenous antibiotic treatment.\n18. Currently suffering from other primary tumors that need active treatment according to the guidelines.\n19. Inability to take drugs orally, previous surgical history, or serious gastrointestinal diseases such as dysphagia and active gastric ulcer may affect the absorption of drugs.\n20. Pregnant (serum pregnancy test results are positive) or lactating women\n21. Any other diseases, abnormal metabolism, abnormal physical examination, or abnormal laboratory examination with significant clinical significance, according to the researcher's judgment, it is reasonable to suspect that the patient has a certain disease or state that is not suitable for using these two drugs, or it will affect the interpretation of the research results or put the patient in a high-risk situation.","FEMALE",{"count":85,"type":22},33,[26],"To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.",[89,29,90],"Follicular Lymphoma","Relapsed Non-Hodgkin Lymphoma","2025-02-18",{"date":93,"type":35},"2025-02-19",{"date":95,"type":35},"2023-11-22",{"date":97,"type":22},"2027-12-31",{"name":99,"class":42},"The First Affiliated Hospital of Xiamen University"]